Korro Bio, Inc. Annual Report - A Closer Look

Korro Bio, Inc. navigated a transformative year in 2023, marked by a significant merger and a sharpened focus on its innovative RNA editing platform. This summary provides investors with a clear, jargon-free look at the company's operations, financial health, and future direction for the fiscal year ended December 31, 2023.

---

1. Business Overview

A significant business combination fundamentally reshaped Korro Bio, Inc. on November 13, 2023. Frequency Therapeutics, Inc. acquired Korro Bio Ops, Inc. (referred to as 'Legacy Korro'), with the combined entity continuing under the name Korro Bio, Inc. Consequently, the 2023 financial results primarily reflect Frequency Therapeutics' pre-merger operations for most of the year, consolidating Legacy Korro's results only from the acquisition date.

What Korro Bio Does: Korro Bio develops innovative genetic medicines using RNA editing, a precise approach to "correct" messenger RNA (mRNA). Unlike gene editing, which permanently alters DNA, RNA editing aims to restore normal protein function or reduce disease-causing proteins by targeting the RNA level. This technology holds promise for treating a wide range of diseases, from rare genetic disorders to more common conditions, by addressing their root cause.

The company operates within the rapidly evolving genetic medicines industry, an area characterized by significant scientific innovation and a challenging funding environment. The successful merger with Legacy Korro defined the year, transforming Korro Bio's strategic focus and pipeline. Post-merger, the company prioritized and advanced its lead RNA editing programs. For example, KORR-101, targeting Alpha-1 Antitrypsin Deficiency (AATD), successfully completed key preclinical studies, demonstrating proof-of-concept in relevant animal models. Further preclinical data supported the broad applicability and precision of their proprietary RNA editing platform, identifying additional potential development candidates across various therapeutic areas. The combined entity operates under the leadership of Nessan Bermingham, Ph.D. as CEO, supported by a new board of directors and executive team reflecting the merged companies.

---

2. Financial Performance

For the fiscal year ended December 31, 2023, Korro Bio, Inc. reported:

• Revenue: $5.2 million, primarily from collaboration agreements. This represented a decrease from $12.8 million in the prior year.
• Net Loss: A net loss of $115.7 million, compared to a net loss of $88.3 million in 2022.
• Research & Development (R&D) Expenses: Totaled $85.4 million.
• General & Administrative (G&A) Expenses: Were $35.1 million.

---

3. Management's Discussion and Analysis (MD&A) Highlights

This section provides a narrative discussion and analysis of the company's financial condition and operational results.

Results of Operations:

The decrease in revenue for 2023, compared to 2022, primarily resulted from the conclusion of certain collaboration agreements inherited from Frequency Therapeutics before the merger. As a development-stage biotechnology company, Korro Bio's revenue streams remain typically limited and depend on such collaborations or future product sales.

The net loss increased from $88.3 million in 2022 to $115.7 million in 2023. This increase largely stemmed from greater research and development (R&D) investments in the RNA editing platform and pipeline, alongside significant merger-related expenses. R&D expenses rose as the company prioritized and advanced its lead RNA editing programs, including preclinical studies for KORR-101. This reflects the company's strategic focus on accelerating therapeutic candidate development post-merger. General & Administrative (G&A) expenses also increased, mainly due to costs associated with the business combination, such as legal, accounting, and other professional fees, as well as ongoing public company operational costs.

Operational Highlights and Challenges:

• Merger Success: The successful business combination with Legacy Korro was a major achievement. It significantly bolstered the company's pipeline, technology platform, and scientific expertise, creating a more focused genetic medicine company. This allowed for the prioritization of the most promising RNA editing programs.
• Preclinical Validation: Compelling preclinical data for KORR-101 further validated the RNA editing approach.
• Integration Challenges: Integrating two companies presented significant operational and strategic challenges, requiring careful management of resources and personnel.
• Increased Cash Burn: The combined entity's intensified R&D efforts led to an increased cash burn rate, typical for early-stage biotechs, necessitating careful financial management.

Liquidity and Capital Resources:

As of December 31, 2023, the company held approximately $185.3 million in cash, cash equivalents, and marketable securities. Management projects this cash position will fund operations into late 2025. The company primarily uses cash for R&D activities, including preclinical and potential clinical trial expenses, and general and administrative expenses. Historically, the company has financed its operations through equity financings and collaboration agreements. We expect future capital requirements to be substantial to support ongoing research and development, preclinical studies, and potential clinical trials. The ability to raise additional capital will depend on market conditions, pipeline progress, and other factors.

Critical Accounting Policies and Estimates:

Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the financial statement date, and the reported amounts of revenues and expenses during the reporting period. Key areas requiring significant judgment include:

• Revenue recognition
• Research and development expenses
• Stock-based compensation
• Valuation of deferred tax assets

Off-Balance Sheet Arrangements and Contractual Obligations:

As of December 31, 2023, Korro Bio did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. The company's primary contractual obligations include operating lease commitments for its facilities and certain research and development agreements.

---

4. Financial Health

As of December 31, 2023, Korro Bio, Inc. reported approximately $185.3 million in cash, cash equivalents, and marketable securities. Management projects this cash position provides a runway to fund operations into late 2025.

The company has No significant long-term debt, maintaining a relatively strong balance sheet for a development-stage biotech.

As of March 15, 2024, the company had approximately 25.8 million shares of common stock outstanding, with a market capitalization of roughly $150 million.

Korro Bio qualifies as a "smaller reporting company" and a "non-accelerated filer." This classification means the company follows scaled-down reporting requirements, which can reduce administrative costs but also results in less extensive public disclosures compared to larger public companies.

---

5. Risk Factors

Investing in Korro Bio carries significant risks, typical for a clinical-stage biotechnology company:

• Clinical Trial Failure: The primary risk is that drug candidates, including KORR-101, may not prove safe or effective in clinical trials, or may never receive regulatory approval.
• Funding Needs: The company will require substantial additional capital to fund its research and development activities. There is no guarantee that such funding will be available on favorable terms or at all. The broader biotech funding environment has been challenging, which could impact Korro Bio's ability to raise future capital.
• Regulatory Hurdles: Obtaining regulatory approvals (e.g., from the FDA) is a lengthy, expensive, and uncertain process. Regulatory agencies globally are still developing guidelines for novel genetic medicines, which can introduce uncertainty and affect development timelines.
• Competition: The genetic medicine and rare disease fields are highly competitive. Larger pharmaceutical companies and other biotechs develop similar or alternative therapies.
• Intellectual Property: The company relies on patents and other intellectual property protections, which competitors may challenge or prove insufficient.
• Integration Risks: Risks exist in fully integrating the operations, technologies, and personnel of Frequency Therapeutics and Legacy Korro post-merger.
• Reliance on Key Personnel: The company's success depends heavily on its ability to attract and retain highly qualified scientific and management personnel.
• Product Liability: Potential for product liability claims exists if any of its drug candidates are approved and commercialized.

---

6. Competitive Position

Korro Bio aims to differentiate itself through its proprietary ADAR-mediated RNA editing platform. This technology offers the potential for precise, in vivo (inside the body) gene correction without altering the underlying DNA. This approach may offer advantages in safety and reversibility compared to DNA-editing methods.

The company competes with a range of companies in the genetic medicine space, including those developing gene therapies, antisense oligonucleotides (another type of RNA-based medicine), and other RNA-based therapeutics. Key competitors include companies like Wave Life Sciences, Verve Therapeutics, and larger pharmaceutical companies with significant R&D budgets. Korro Bio's focus on specific diseases like AATD with a differentiated RNA editing approach forms the core of its competitive strategy. Continuous breakthroughs in gene editing and RNA technologies present both opportunities for platform enhancement and competitive pressures from new therapeutic modalities.

---

7. Future Outlook

Looking ahead, Korro Bio focuses on advancing its lead programs and expanding its RNA editing platform. Key strategic shifts post-merger include a clear prioritization of the RNA editing pipeline, with KORR-101 for AATD as the lead program, and continued investment in expanding the RNA editing platform to address a broader range of genetic diseases.

• KORR-101: The company anticipates filing an Investigational New Drug (IND) application for KORR-101 in mid-2024, with the goal of initiating a Phase 1 clinical trial shortly thereafter.
• Pipeline Expansion: Expect to identify additional development candidates from their platform and potentially present preclinical data for other programs, such as those targeting neurological disorders, at scientific conferences in late 2024.
• Strategic Partnerships: The company may explore strategic collaborations to further develop its platform or specific programs, especially for indications outside its core focus.
• Capital Management: Korro Bio will continue to focus on prudent capital allocation to extend its cash runway and fund critical R&D initiatives.
• Operational Efficiency: Efforts to optimize operational efficiencies and resource allocation following the merger will continue.
• Patient Advocacy: Growing patient advocacy for rare diseases could positively impact Korro Bio's programs by accelerating drug development and access.